These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 37071946)

  • 41. Receipt of medications for opioid use disorder before and after incarceration in Massachusetts State prisons, 2014-2019.
    Bovell-Ammon BJ; Yan S; Dunn D; Evans EA; Friedmann PD; Walley AY; LaRochelle MR
    Drug Alcohol Depend; 2024 Sep; 262():111392. PubMed ID: 39029371
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Incarceration and compulsory rehabilitation impede use of medication for opioid use disorder and HIV care engagement in Vietnam.
    King C; Cook R; Giang LM; Bart G; Hoffman K; Waddell EN; Korthuis PT
    J Subst Abuse Treat; 2022 Mar; 134():108451. PubMed ID: 33962813
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Does incarceration influence patients' goals for opioid use disorder treatment? A qualitative study of buprenorphine treatment in jail.
    Vail W; Faro E; Watnick D; Giftos J; Fox AD
    Drug Alcohol Depend; 2021 May; 222():108529. PubMed ID: 33810909
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Jail-based medication for opioid use disorder and patterns of reincarceration and acute care use after release: A sequence analysis.
    Lim S; Cherian T; Katyal M; Goldfeld KS; McDonald R; Wiewel E; Khan M; Krawczyk N; Braunstein S; Murphy SM; Jalali A; Jeng PJ; Rosner Z; MacDonald R; Lee JD
    J Subst Use Addict Treat; 2024 Mar; 158():209254. PubMed ID: 38072387
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Budget impact tool for the incorporation of medications for opioid use disorder into jail/prison facilities.
    Ryan DA; Montoya ID; Koutoujian PJ; Siddiqi K; Hayes E; Jeng PJ; Cadet T; McCollister KE; Murphy SM
    J Subst Use Addict Treat; 2023 Mar; 146():208943. PubMed ID: 36880906
    [TBL] [Abstract][Full Text] [Related]  

  • 46. 28-year-old Woman With Opioid Use Disorder Delivers Healthy Baby While in Custody: Addressing Forced Detox.
    Gray J; Saia K; Walley AY
    J Addict Med; 2019; 13(3):237-240. PubMed ID: 30379779
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Spatial and Nonspatial Factors Associated with Access to Medication for Opioid Use Disorder among Pregnant Women in Massachusetts.
    Joshi C; Ho Chui KK; Skeer MR; Stopka TJ
    Subst Use Misuse; 2022; 57(13):1904-1917. PubMed ID: 36219099
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Optimizing the impact of medications for opioid use disorder at release from prison and jail settings: A microsimulation modeling study.
    Macmadu A; Adams JW; Bessey SE; Brinkley-Rubinstein L; Martin RA; Clarke JG; Green TC; Rich JD; Marshall BDL
    Int J Drug Policy; 2021 May; 91():102841. PubMed ID: 32712165
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Assessing the impact of jail-initiated medication for opioid use disorder: A multisite analysis of the SOMATICS collaborative.
    Lee JD; Goldfeld K; Schwartz RP; McDonald R; Xu Y; Chandler R; Hallgren K; Kelly SM; Mitchell SG; Sharma A; Farabee D
    PLoS One; 2024; 19(6):e0305165. PubMed ID: 38885220
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Drug court utilization of medications for opioid use disorder in high opioid mortality communities.
    Marlowe DB; Theiss DS; Ostlie EM; Carnevale J
    J Subst Abuse Treat; 2022 Oct; 141():108850. PubMed ID: 35931014
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The Transitions Clinic Network: Post Incarceration Addiction Treatment, Healthcare, and Social Support (TCN-PATHS): A hybrid type-1 effectiveness trial of enhanced primary care to improve opioid use disorder treatment outcomes following release from jail.
    Howell BA; Puglisi L; Clark K; Albizu-Garcia C; Ashkin E; Booth T; Brinkley-Rubinstein L; Fiellin DA; Fox AD; Maurer KF; Lin HJ; McCollister K; Murphy S; Morse DS; Shavit S; Wang K; Winkelman T; Wang EA
    J Subst Abuse Treat; 2021 Sep; 128():108315. PubMed ID: 33583610
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Post-incarceration outcomes for individuals who continued methadone treatment while in Connecticut jails, 2014-2018.
    Haas A; Viera A; Doernberg M; Barbour R; Tong G; Grau LE; Heimer R
    Drug Alcohol Depend; 2021 Oct; 227():108937. PubMed ID: 34371235
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Evolving Medicolegal Precedent for Medications for Opioid Use Disorder in U.S. Jails and Prisons.
    Toyoshima T; McNiel DE; Schonfeld A; Binder R
    J Am Acad Psychiatry Law; 2021 Dec; 49(4):545-552. PubMed ID: 34341145
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Changes In County-Level Access To Medications For Opioid Use Disorder After Medicare Coverage Of Methadone Treatment Began.
    Harris SJ; Yarbrough CR; Abraham AJ
    Health Aff (Millwood); 2023 Jul; 42(7):991-996. PubMed ID: 37406230
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Availability of best practices for opioid use disorder in jails and related training and resource needs: findings from a national interview study of jails in heavily impacted counties in the U.S.
    Scott CK; Grella CE; Dennis ML; Carnevale J; LaVallee R
    Health Justice; 2022 Dec; 10(1):36. PubMed ID: 36538121
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Medication for opioid use disorder treatment continuity post-release from jail: A qualitative study with community-based treatment providers.
    Stopka TJ; Rottapel RE; Ferguson WJ; Pivovarova E; Toro-Mejias LD; Friedmann PD; Evans EA
    Int J Drug Policy; 2022 Dec; 110():103803. PubMed ID: 35965159
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Examining differences in retention on medication for opioid use disorder: An analysis of Ohio Medicaid data.
    Zhang P; Tossone K; Ashmead R; Bickert T; Bailey E; Doogan NJ; Mack A; Schmidt S; Bonny AE
    J Subst Abuse Treat; 2022 May; 136():108686. PubMed ID: 34953637
    [TBL] [Abstract][Full Text] [Related]  

  • 58. "You have to take this medication, but then you get punished for taking it:" lack of agency, choice, and fear of medications to treat opioid use disorder across the perinatal period.
    Schiff DM; Work EC; Muftu S; Partridge S; MacMillan KDL; Gray JR; Hoeppner BB; Kelly JF; Greenfield SF; Jones HE; Wilens TE; Terplan M; Bernstein J
    J Subst Abuse Treat; 2022 Aug; 139():108765. PubMed ID: 35341614
    [TBL] [Abstract][Full Text] [Related]  

  • 59. College students' perceived knowledge of and perceived helpfulness of treatments for opioid use disorder at two American universities.
    Andraka-Christou B; Nguyen T; Harris S; Madeira J; Totaram R; Randall-Kosich O; Atkins D; Ford J
    Am J Drug Alcohol Abuse; 2020 Sep; 46(5):589-603. PubMed ID: 32543922
    [No Abstract]   [Full Text] [Related]  

  • 60. Beliefs about medications for opioid use disorder among Florida criminal problem-solving court & dependency court staff.
    Andraka-Christou B; Atkins D
    Am J Drug Alcohol Abuse; 2020 Nov; 46(6):749-760. PubMed ID: 32969757
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.